We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $28.53, marking a +2.88% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.6%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.64%.
Shares of the company have depreciated by 13.69% over the course of the past month, underperforming the Medical sector's loss of 1.97%, and the S&P 500's gain of 1.34%.
The investment community will be paying close attention to the earnings performance of Viking Therapeutics, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$1, marking a 23.46% fall compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.46 per share and a revenue of $0 million, signifying shifts of -39.81% and 0%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Viking Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 29% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Viking Therapeutics, Inc. (VKTX - Free Report) closed at $28.53, marking a +2.88% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.6%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.64%.
Shares of the company have depreciated by 13.69% over the course of the past month, underperforming the Medical sector's loss of 1.97%, and the S&P 500's gain of 1.34%.
The investment community will be paying close attention to the earnings performance of Viking Therapeutics, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$1, marking a 23.46% fall compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.46 per share and a revenue of $0 million, signifying shifts of -39.81% and 0%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Viking Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 29% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.